Loading ...
Sorry, an error occurred while loading the content.

FDA Approves Roche Hepatitis C Drug

Expand Messages
  • claudine intexas
    FDA Approves Roche Hepatitis C Drug Tue Dec 3,10:53 PM ET WASHINGTON (Reuters) - The U.S. Food and Drug Administration (news - web sites) said on Tuesday it
    Message 1 of 1 , Dec 3, 2002
      FDA Approves Roche Hepatitis C Drug
      Tue Dec 3,10:53 PM ET

      WASHINGTON (Reuters) - The U.S. Food and Drug Administration (news -
      web sites) said on Tuesday it had approved Roche Holding AG's Pegasys
      drug in combination with another anti-viral compound to treat
      hepatitis C, a potential blockbuster product for the Swiss-based

      Up to 4 million Americans are estimated to be infected with the
      hepatitis C virus that slowly attacks the liver and sometimes kills.

      An FDA advisory panel last month unanimously recommended approval of
      Pegasys in combination with the antiviral drug ribavirin. The FDA
      normally follows the recommendations of its advisory panels.

      Pegasys is a once-a-week, long-acting, injectable version of the
      antiviral protein interferon, and daily doses of Copegus, Roche's
      version of the ribavirin pill.

      The FDA in October gave Pegays clearance as a stand-alone treatment
      for hepatitis C but approval for the combination is seen as crucial
      for Roche to compete with a similar combination therapy by
      Schering-Plough Corp.

      Pegasys has already received European approval for use alone or in
      combination with ribavirin.

      "Today, Roche can proudly offer Americans with hepatitis C a new
      treatment choice," Hoffmann Roche Inc. President and Chief Executive
      Officer George Abercrombie said in a statement.

      The drug is especially important for Roche which industry analysts
      says has a relatively thin new-product pipeline.

      Roche, which has climbed back into the ranks of the world's top 10
      drugmakers by acquiring Japan's Chugai Pharmaceutical Co. Ltd. this
      year, is counting on Pegasys and HIV (news - web sites) drug Fuzeon
      to help it generate double-digit 2003 drug sales growth.

      Roche drugs division head William Burns told Reuters last month he
      expects sales of its Pegasys drug combined with ribavirin to build
      slowly toward $1 billion a year over three to five years once it wins
      U.S. approval.

      Hepatitis C is biggest cause of liver transplants in the United
      States but the disease develops slowly, often over 20 years, before
      symptoms of liver failure emerge.

      Schering-Plough's rival long-acting interferon, called Peg-Intron, is
      also given weekly by injection, with patients also taking daily
      ribavirin pills.

      Sales of Peg-Intron and Schering-Plough's brand of ribavirin more
      than doubled to $703 million in the third quarter, making hepatitis C
      the company's biggest business.

      Patients flocked to Schering-Plough's dual therapy after it was
      launched in October 2001 because it is more effective and causes
      fewer side effects than the company's older treatment using an
      interferon that had to be taken three times a week.

      Schering-Plough's improved therapy is considered the "gold standard"
      of treatment, with about 56 percent of patients taking it eliminating
      all traces of hepatitis C after 48 weeks of medication.

      With Roche's Pegasys combination, 50 percent of people having no
      detectable virus in their blood six months after treatment concluded,
      Roche officials told the FDA advisory panel last month. Using an
      older interferon, injected three times a week, with ribavirin, only
      42 percent of patients cleared the virus.

      With Pegasys alone, the treatment was effective in 27 percent of

      Roche is also testing Pegasys against hepatitis B, a form of the
      disease that is a large problem in Asia.

      Do you Yahoo!?
      Yahoo! Mail Plus - Powerful. Affordable. Sign up now.
    Your message has been successfully submitted and would be delivered to recipients shortly.